Q-Vant Biosciences collaborates with Tulane University to develop a promising new oral vaccine adjuvant
Q-Vant Biosciences Inc., a biosciences company specialized in manufacturing and formulating open-access saponin-based adjuvants from sustainable sources announced that it has entered a research collaboration with Tulane University to develop a novel and innovative...
Q-VANT and SPI Pharma offering broader access to sustainable and scalable pharma-grade saponin adjuvants
SPI Pharma, Inc. and Q-Vant Biosciences, Inc. announce a strategic partnership which includes an investment to expand Q-Vant's proprietary 100% sustainable Q-SAP™ technology, and the signing of an exclusive commercial agreement to accelerate global adoption of...
windows 10 activator txt cmd ✓ Activate Windows 10 Fast 2 Easy Steps
windows 10 activator txt cmd Activate Windows 10 using a script-based tool with command prompt commands ✓ Step-by-step guide ➤ Execute commands ★ No product key needed
Q-Vant Biosciences Announces Positive Study Results for Its Sustainable Quillaja-Based Vaccine Adjuvant, Q-VET-S®, in Kansas State’s Classic Swine Fever Vaccine
BOSTON, MA May 23, 2023 – Q-Vant Biosciences, the first company to achieve a 100% sustainable way to meet the growing global vaccine market demand for Quillaja saponin-based adjuvants, today announced very positive results comparing Q-Vant's sustainable saponin-based...
Q-VANT Biosciences enters Vaccine Research Master Agreement with Kansas State University Teams to study the impact of saponin-based adjuvants on animal vaccine efficacy
BOSTON, MA – April 12, 2022 – Q-VANT Biosciences, the first company to achieve a 100% sustainable way to meet the growing global vaccine market demand for Quillaja saponin-based adjuvants, today announced that it has signed a Master Agreement with Kansas State...
Q-VANT and In vitro Plant-tech Sign Agreement for the Development and Supply of Quillaja saponaria Plant Cell Culture Biomass
Enhances Q-VANT’s 100% sustainable supply for next-generation saponin adjuvants Boston, MA – March 8, 2022 – Q-VANT Biosciences, the first company to achieve a 100% sustainable way to meet the growing global vaccine market demand for Quillaja saponin-based adjuvants,...
Q-VANT Biosciences Launches to Solve the Pharmaceutical Industry Problem of Limited Quillaja Saponin-Based Adjuvants for Life-Saving Vaccines
Company’s Innovative Technology Increases Yield of High-Quality Saponin-Based Adjuvants, Enabling the Sustainable Supply of Billions of Doses Annually BOSTON, MA – January 6, 2022 – Q-VANT Biosciences has launched as the first bioscience company to achieve a 100%...
Q-VANT’s Chief Scientific Officer Shares Insights Gleaned from His Decades in Vaccine Development
Bruce Forrest recently joined the Q-VANT team as Chief Scientific Officer, bringing more than two decades of experience in vaccine and adjuvant development and commercialization. A former senior vice president of R&D with Pfizer/Wyeth Vaccines, Bruce has a global...
QS-21 and the Quillaja Tree
The Quillaja saponaria tree is a slow-growing evergreen native to Chile whose bark has long been used for medicinal and commercial purposes. Quillaja bark is an abundant source of saponins, a group of organic compounds that are used as an emulsifier and foaming agent...
QS-21 Supply Chain Challenges
Q-VANT Biosciences launched recently as the first company to use a computational-driven approach to solve the supply chain problem of QS-21 and other quillaja-based saponin adjuvants for the global human and animal pharmaceutical markets. The company’s arrival on the...